Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

<p>Supplementary Dataset S9</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Cara Abecunas (14960274) (author)
Andere auteurs:	Christopher E. Whitehead (14960277) (author), Elizabeth K. Ziemke (14960280) (author), Douglas G. Baumann (14960283) (author), Christy L. Frankowski-McGregor (14960286) (author), Judith S. Sebolt-Leopold (14960289) (author), Mohammad Fallahi-Sichani (14960292) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Drug Targets Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Systems Biology
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S3 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S5 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S7 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
door: Cara Abecunas (14960274)
Gepubliceerd in: (2025)

Table S9 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Figure S1 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Figure S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Figure S3 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Figure S4 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Figure S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S10 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S11 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S12 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S3 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S4 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Table S8 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma
door: Milad Ibrahim (22053777)
Gepubliceerd in: (2025)

Supplementary Tables from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
door: Kohei Takano (15093373)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
door: James S. Wilmott (15008931)
Gepubliceerd in: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
door: James S. Wilmott (15008931)
Gepubliceerd in: (2025)

Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
door: Prashanthi Dharanipragada (14837251)
Gepubliceerd in: (2025)

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.
door: Fengyi Mao (15073242)
Gepubliceerd in: (2025)

Table 9_Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response.xlsx
door: Zhaoqi Zhang (332445)
Gepubliceerd in: (2025)

Supplemental Table S9 from Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
door: Joanna Pozniak (21652493)
Gepubliceerd in: (2025)

CST gene alterations and expression in cutaneous melanoma tissues.
door: Sara Knowles (15277363)
Gepubliceerd in: (2025)

Supplementary Tables S6-S9 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
door: Ka-Won Noh (22618441)
Gepubliceerd in: (2025)

Supplementary Figure from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Figure from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Figure from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Figure from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Figure from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Table from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Table from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Supplementary Table from A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma
door: Weijia Cai (15099353)
Gepubliceerd in: (2025)

Table 1_Melanoma in Chile: demographics and clinico-pathological features.xlsx
door: Erica C. Koch Hein (22211215)
Gepubliceerd in: (2025)